Tecovirimat Solubility via Cyclodextrin Meglumine Ternary Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tecovirimat, a potent small-molecule virus inhibitor for smallpox, has poor water solubility, limiting its clinical application, and existing solubilization methods do not sufficiently enhance its solubility for effective therapeutic use.
Innovation Solution
A ternary solubilizing composition comprising Tecovirimat, cyclodextrin, and meglumine, which significantly increases Tecovirimat's solubility up to 152 mg/ml, offering a simple formulation process, stable quality, strong controllability, good reproducibility, and low cost, while reducing the amount of cyclodextrin needed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Tecovirimat is used as a therapeutic agent for smallpox, then its antiviral efficacy is improved, but its poor water solubility limits its clinical application
Solution Approach 1:
The patent uses cyclodextrin as an intermediary substance to solubilize Tecovirimat. Cyclodextrin forms an inclusion complex with Tecovirimat, where the hydrophobic Tecovirimat molecule is encapsulated within the cyclodextrin cavity, thereby improving its water solubility while maintaining antiviral activity. This mediator approach resolves the contradiction between efficacy and solubility.
Solution Approach 2:
The patent changes the physical-chemical parameters of the formulation by adjusting the concentration of cyclodextrin and optimizing the pH value. By modifying these parameters, the solubility of Tecovirimat is enhanced without compromising its antiviral efficacy, thus resolving the solubility limitation.
2Ease of operation
If high concentration of cyclodextrin is used to improve Tecovirimat solubility, then solubility is enhanced, but formulation complexity and cost increase
Solution Approach 1:
The patent optimizes the cyclodextrin concentration to achieve maximum solubility enhancement at a moderate concentration level, avoiding the need for excessively high concentrations that would increase formulation complexity. The optimal ratio of cyclodextrin to Tecovirimat is determined through systematic parameter optimization.
Solution Approach 2:
The patent creates a composite formulation consisting of Tecovirimat, cyclodextrin, and auxiliary substances. This composite approach allows for synergistic effects where the combination of components achieves superior solubility enhancement compared to individual substances, while maintaining formulation simplicity.
3Object-affected harmful factors
If Tecovirimat is combined with smallpox vaccine, then adverse reactions are reduced and wound healing is promoted, but the complexity of treatment regimen increases
Solution Approach 1:
The patent combines Tecovirimat with smallpox vaccine in a single pharmaceutical composition. This merging of the antiviral agent and vaccine into one formulation simplifies the treatment regimen by eliminating the need for separate administration of multiple substances, while still providing the benefit of reduced adverse reactions and promoted wound healing.
Solution Approach 2:
The pharmaceutical composition serves multiple functions simultaneously: it provides antiviral protection, reduces adverse reactions to the vaccine, and promotes wound healing. This multi-functionality in a single formulation reduces treatment complexity while addressing multiple therapeutic needs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides a stable and highly soluble form of Tecovirimat, enhancing its clinical application by improving solubility, stability, and reducing adverse reactions, making it suitable for injection and treatment of smallpox.
Implementation Method 1
Tecovirimat is solubilized in cyclodextrin
Implementation Method 2
a novel ternary solubilizing composition comprising Tecovirimat, cyclodextrin, and an additive Meglumine
Data Source
AI summary
The present invention relates to a pharmaceutical composition of Tecovirimat for injection, comprising Tecovirimat as an active ingredient, cyclodextrin and an additive. The present invention also relates to a method for preparing the pharmaceutical composition. The composition improves the solubility of Tecovirimat in water by using cyclodextrin and meglumine in combination, as compared with the solubility of Tecovirimat in water by using cyclodextrin or meglumine alone.